Modes of action of five antirhinovirus agents were compared. Ro 09-0410, 4',6-dichloroflavan, and RMI-15,731 were active preferentially against human rhinovirus. Serotypes of the virus varied in their susceptibility to these three agents, whereas Ro 09-0179 and enviroxime showed activity against all the serotypes of the virus tested to date. Ro 09-0410, RMI-15,731, and 4',6-dichloroflavan inactivated the virus directly, although 4',6-dichloroflavan did so only slightly. Inactivation by 4', 731 was associated with the binding of the agents to the virus, since the infectivity, reduced by exposure to the agents, was restored to the original level by extraction of the agents with chloroform. The binding of [3H]Ro 09-0410 to human rhinovirus type 2 was inhibited by unlabeled Ro 09-0410, 4',6-dichloroflavan, and RMI-15,731 but not by Ro 09-0179 or enviroxime. Furthermore, subtypes resistant to both 4',6-dichloroflavan and RMI-15,731 showed cross-resistance to Ro 09-0410 and vice versa. On the other hand, sublines resistant to these three agents were not cross-resistant to Ro 09-0179 or enviroxime. These results indicate (i) that Ro 09-0410, 4',6-dichloroflavan, and RMI-15,731 exert their activities through the same mode of action, namely, binding to or interaction with some specific site on the viral capsid protein, and (ii) that the binding or interaction sites for these three agents are either the same or very close to each other.
As reported previously, an antirhinovirus chalcone, Ro 09-0410 (4'-ethoxy-2'-hydroxy-4,6'-dimethoxy chalcone) ( Fig. 1 ) directly inactivated only human rhinoviruses (HRV) (4) . It bound to HRV at the specific site on the capsid protein not found on degraded HRV or viruses insensitive to the agent and stabilized the virus particles in such a way that HRV bound to the agent resisted the conformational change in virion size induced by low pH or elevated temperature (56°C) (11) . We suggested that Ro 09-0410 interfered with the conformational change occurring during the uncoating process in the cells (11) . Antiviral agents, 4',6-dichloroflavan (2) and RMI-15,731 (1-[5-tetradecyloxy-2-furanyl]-ethanone) (1), seem to have a mode of action against HRV similar to that of Ro 09-0410. These agents are active preferentially against HRV but not against other viruses. Furthermore, RMI-15,731 inactivated HRV directly (1), whereas 4',6-dichloroflavan bound to some extent to HRV (2) . On the other hand, enviroxime (LY122772; anti-6-[(hydroxyimino)-phenylmethyl]-1-[(1-methylethyl)sulfonylimidazol-2-amine) (3) and Ro 09-0179 (4',5-dihydroxy-3,3',7-trimethoxyflavone) (5) exhibited different modes of action, possibly inhibiting viral replication at the process of viral RNA synthesis. The structures of these agents are shown in Fig. 1 .
In the present study, we examined the antirhinovirus activities of the five agents referred to above and their abilities to interact with HRV type 2. These studies indicate that Ro 09-0410, RMI-15,731, and 4',6-dichloroflavan exert their activity by the same mode of action, binding to or interacting with a specific site on the virus capsid. This has been further confirmed by the fact that HRV (type 2) sublines resistant to 4',6-dichloroflavan and RMI-15,731 were cross-resistant to Ro 09-0410 and vice versa. * Corresponding author.
MATERIALS AND METHODS
Cells and viruses. HeLa cells (Bristol strain) were grown and used for viral titration by a plaque assay method as described elsewhere (5) . HRV and guinea pig anti-HRV type 2 serum (ATCC VR-1112 AS/GP) were purchased from the American Type Culture Collection, Rockville, Md. Sublines of HRV type 2 which are resistant to each of the antivirus agents used in this study were isolated by continuous passage in HeLa cell culture in the presence of sublethal concentrations of the antiviral agents. Briefly, HeLa cells were infected with HRV type 2 in Eagle minimum essential medium containing 2% fetal calf serum, 1% tryptose phosphate broth, 10 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid) buffer (pH 7.2), 50 ,ug of streptomycin sulfate per ml, 50 U of penicillin G per ml, and 0.33, 1, 3, or 9 50% inhibitory concentrations (IC50s) ofthe antiviral agents. After incubation at 33°C for 4 or 5 days, cells showing cytopathogeneic effects at the highest IC50 of an agent were harvested and homogenized. This transfer through increasing concentrations of the antiviral agent was repeated several times. Finally, sublines resistant to elevated concentrations of the agents were isolated as single plaques in monolayers of HeLa cells overlaid with Eagle minimum essential medium containing 5% fetal calf serum, 1% tryptose phosphate broth, 10 mM HEPES buffer (pH 7.2), 50 ,ug of DEAE-dextran per ml, 10 mM MgC92, 50 ,ug of streptomycin sulfate per ml, 50 U of penicillin G per ml, 0.8% Noble agar, and the antiviral agents.
Chemicals. Ro 09-0410 (4'-ethoxy-2'-hydroxy-4,6'-dimethoxychalcone) and Ro 09-0179 (4',5-dihydroxy-3,3'-7-trimethoxyflavone) used in this report were synthesized as described by M (Table  2) . 4',6-Dichloroflavan inactivated HRV type 16 only, although it was highly active against other serotypes by the IC50 assay (Table 1) . None of the serotypes was inactivated by either Ro 09-0179 or enviroxime ( Table 2) .
As reported previously, the infectivity of HRV type 2, reduced by exposure to Ro 09-0410, was completely reversible when the agent was extracted with chloroform (11) . The infectivity of HRV type 2 was restored by extraction of both RMI-15,731 and Ro 09-0410 (Table 3) . Similarly, the infec- 09-0410 in the presence of an excess amount of unlabeled Ro 09-0410 at a ratio of 1:38, the binding of the radioactive compound was inhibited (Fig. 2B) . Binding was also inhibited by 4',6-dichloroflavan (0.5 Fig/ml) and to a lesser extent by RMI-15,731 (0.5 p.g/ml), at which the molar ratios of [3H]Ro 09-0410 to these agents were 1:32 and 1:37, respectively ( Fig. 2C and D) . These results suggest that either the binding sites for these three agents on HRV type 2 are very similar, differences in chemical structure not withstanding, or the binding site for Ro 09-0410 is changed topologically by interaction with the other two agents. As for Ro 09-0179 and enviroxime, these agents did not compete for the binding of [3H]Ro 09-0410 ( Fig. 2E and F) , indicating that their modes of action are completely different from those of the other three.
Studies on cross-resistance of HRV type 2 sublines resistant to the individual test agents. Subtypes of HRV type 2, NR2-410, NR2-DCF, and NR2-RMI, which are resistant to Ro 09-0410, 4',6-dichloroflavan, or RMI-15,731, were acquired by serial passages of the virus in the presence of sublethal concentrations of these agents. These sublines were 9 to 370 times less susceptible to the agents than the original subtypes, whereas their antigenicity detected by neutralizing antibody remained unchanged ( DISCUSSION The present study shows that antiviral agents, Ro 09-0410, 4',6-dichloroflavan, and RMI-15,731, which are active exclusively against HRV, exert the activity through the same mode of action, whereas Ro 09-0179 and enviroxime, which are active against most picornaviruses, have different modes of action. The former group was suggested to bind to or interact with similar sites on the capsid and make the virus inactive.
A possible obstacle to acceptance of the conclusion that Ro 09-0410, RMI-15,731, and 4',6-dichloroflavan have the same mode of action is that these three agents differ significantly with respect to their activities against susceptible subtypes of HRV (Table 1) . Conformation of the binding site on the capsid may be slightly different among HRV serotypes. The conformation on some serotypes may favor one agent, but that on other serotypes may favor the other agents. Another obstacle to acceptance of the conclusion is that the virus-inactivating activity of 4',6-dichloroflavan is not associated with the activity measured by the IC50 assay (Tables 1 and 2) . A possible explanation is that binding of either Ro 09-0410 or RMI-15,731 occurs irreversibly in an aqueous solution, whereas 4',6-dichloroflavan interacts somewhat reversibly with HRV type 2 but irreversibly with HRV. type 16. In the IC50 assay, the agents are present in culture medium throughout the assay. In the assay for virus inactivation' HRV (106 to 107 PFU/ml) exposed to the agents (0.5, 1, or 10 jiggml) was diluted to about a 10-3 to 10-5 level to avoid interference of the agents with titration of the residual virus. Therefore, agents which inactivate HRV through reversible interaction, could not show activity in this assay. Instability of HRV at a pH below 6 or at 56°C is the most common characteristic that distinguishes it from other human picornaviruses (10, 12) . Acid and heating at 560C caused alteration in size, conformation, and antigenicity of the virus (6, 7, 9) . The same type of alteration was observed in infected cells during the uncoating process (8) . Since Ro 09-0410 that bound to the virus prevented it from alteration caused by treatment at pH 5 or 56°C, it was suggested that Ro 09-0410 stabilizes the virus particles in such a way that the virus does not proceed to the uncoating process (11) .
RMI-15,731 and 4',6-dichloroflavan may exert antiviral activities by a similar mechanism, and the capsid protein bound to these agents must be important for triggering the uncoating process in the replication of HRV. Further details remain to be investigated.
The activity of Ro 09-0179 and enviroxime was not associated with the capsid protein, to which the other three agents were bound. As reported previously (5), Ro 09-0179 interfered with replication of HRV type 2 at the process after uncoating and inhibited formation of the RNA polymerase complex, a machinery for viral RNA synthesis. Enviroxime also showed similar activity (C. Y. E. Wu, L. D. Nelson, B. R. Warren, and D. C. Delong, Abstr. Annu. Meet. Am. Soc. Microbiol. 1978, S128, p. 234). We tried to isolate sublines resistant to Ro 09-0179 and enviroxime but had no success. The sites of viral proteins with which Ro 09-0179 and enviroxime associate may be important for virus replication to an extent that amino acid sequences of the sites are genetically conservative and that mutation at these sites is lethal. Any other possible explanation is that these agents act on cellular functions required for virus replication.
